FDA Approves Belzutifan and Pembrolizumab for Adjuvant Renal Cell Carcinoma Treatment

The FDA has approved the combination of belzutifan and pembrolizumab as an adjuvant therapy for adults with clear cell renal cell carcinoma. According to a press release, the treatment targets patients at intermediate-high or high risk of recurrence following nephrectomy or the resection of metastatic lesions.

This approval allows belzutifan, marketed as Welireg by Merck, to be used alongside pembrolizumab (Keytruda) or a combination of pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex), both also produced by Merck.

Who can receive this new adjuvant therapy?

The treatment is specifically for adults with renal cell carcinoma that has a clear cell component. According to the FDA, these patients must be at an intermediate-high or high risk of the cancer returning after they have undergone a nephrectomy.

The approval also extends to those who have had both a nephrectomy and the resection of metastatic lesions. The therapy serves as an adjuvant treatment, meaning it’s used to prevent the return of cancer after the primary tumor has been removed.

How was the efficacy of the combination proven?

The FDA based its decision on data from the randomized LITESPARK-022 trial. According to the press release, the trial found that combining belzutifan with pembrolizumab resulted in statistically significant improvements in disease-free survival.

This combination performed better than the control group, which received pembrolizumab paired with a placebo. These findings were presented by Choueiri TK, et al., in Abstract LBA418 at the ASCO Genitourinary Cancers Symposium held Feb. 26-28, 2026, in San Francisco.

Did You Know? The FDA’s approval was supported by the LITESPARK-022 trial, which specifically measured “disease-free survival” to determine if the combination therapy could keep cancer from returning longer than current options.

What are the recommended dosages and timelines?

For belzutifan, the FDA recommends a dose of 120 mg taken orally once daily. This treatment may continue until the disease recurs, toxicity occurs, or for a maximum of 54 weeks.

FDA D.I.S.C.O. Burst Edition: FDA approval of Keytruda (pembrolizumab) as adjuvant treatment for …

Pembrolizumab administration varies by method. The FDA recommends 200 mg via IV every 3 weeks or 400 mg every 6 weeks. For those using the subcutaneous version with berahyaluronidase alfa-pmph, the dose is 395 mg/4,800 units every 3 weeks or 790 mg/9,600 units every 6 weeks.

Treatment with pembrolizumab or the subcutaneous combination is recommended to last until disease recurrence, toxicity, or for 12 months.

Expert Insight: Samantha Carter notes that the approval of a combination regimen for high-risk patients suggests a shift toward more aggressive adjuvant strategies. By targeting different pathways simultaneously, clinicians may be better equipped to manage patients who face a significant likelihood of recurrence.

What may happen next for high-risk patients?

Patients who previously relied on single-agent therapies may now have a combination option to discuss with their oncology teams. This could lead to a change in standard care protocols for those categorized as intermediate-high or high risk.

Because the therapy is limited by toxicity or specific timeframes (54 weeks for belzutifan and 12 months for pembrolizumab), clinicians will likely need to monitor patients closely for adverse effects during the treatment window.

Frequently Asked Questions

What specific type of kidney cancer is this approved for?
It is approved for adults with renal cell carcinoma that has a clear cell component.

How is belzutifan administered?
Belzutifan is taken as an oral medication at a dose of 120 mg once daily.

What trial provided the evidence for this approval?
The FDA cited data from the randomized LITESPARK-022 trial, which showed improved disease-free survival compared to placebo plus pembrolizumab.

How do you feel about the use of combination therapies to prevent cancer recurrence?